Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study.
Senna G, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Cameli P, Canonica GW, Caruso C, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, Rizzoli S, Zullo A, Boarino S, Palmisano M, Rossi A, Vitiello G, Centanni S. Senna G, et al. Among authors: caiaffa mf. J Asthma Allergy. 2022 Nov 10;15:1593-1604. doi: 10.2147/JAA.S383012. eCollection 2022. J Asthma Allergy. 2022. PMID: 36387835 Free PMC article.
Italian real-life experience of omalizumab.
Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, Berra A, Schino P, Di Napoli PL, Maselli R, Pelaia G, Bucchioni E, Paggiaro PL, Macchia L. Cazzola M, et al. Among authors: caiaffa mf. Respir Med. 2010 Oct;104(10):1410-6. doi: 10.1016/j.rmed.2010.04.013. Epub 2010 May 18. Respir Med. 2010. PMID: 20483574 Free article.
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes.
Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Ricci A, Cresti A, Santus P, Olivieri C, Perrella A, Rogliani P, Paggiaro P; Omalizumab Italian Study Group. Sposato B, et al. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1643-1646. doi: 10.1016/j.jaip.2019.03.006. Epub 2019 Mar 19. J Allergy Clin Immunol Pract. 2019. PMID: 30898690 No abstract available.
Characteristics and treatment regimens across ERS SHARP severe asthma registries.
van Bragt JJMH, Adcock IM, Bel EHD, Braunstahl GJ, Ten Brinke A, Busby J, Canonica GW, Cao H, Chung KF, Csoma Z, Dahlén B, Davin E, Hansen S, Heffler E, Horvath I, Korn S, Kots M, Kuna P, Kwon N, Louis R, Plaza V, Porsbjerg C, Ramos-Barbon D, Richards LB, Škrgat S, Sont JK, Vijverberg SJH, Weersink EJM, Yasinska V, Wagers SS, Djukanovic R, Maitland-van der Zee AH; SHARP Clinical Research Collaboration; Members of the SHARP Clinical Research Collaboration are. van Bragt JJMH, et al. Eur Respir J. 2020 Jan 9;55(1):1901163. doi: 10.1183/13993003.01163-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31601713 Free article.
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.
Bagnasco D, Povero M, Pradelli L, Brussino L, Rolla G, Caminati M, Menzella F, Heffler E, Canonica GW, Paggiaro P, Senna G, Milanese M, Lombardi C, Bucca C, Manfredi A, Canevari RF, Passalacqua G; SANI Network (Severe Asthma Network Italy). Bagnasco D, et al. World Allergy Organ J. 2021 Jan 27;14(2):100509. doi: 10.1016/j.waojou.2021.100509. eCollection 2021 Feb. World Allergy Organ J. 2021. PMID: 33598095 Free PMC article.
73 results